|
Allos Therapeutics Stage: Venture Date of Investment: 2005, 2008 Web Site : http://www.allos.com Stock Symbol : NASDAQ: ALTH |
 |
Allos Therapeutics, Inc., based in Westminster, Colorado, is a pharmaceutical company focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company’s lead drug, Folotyn, was approved in September 2009 as the first FDA-approved drug for the treatment of relapsed or refractory peripheral T-cell lymphoma, a rare cancer whose sufferers have a very poor prognosis. Allos continues to advance several additional clinical studies of Folotyn in a wide range of other cancer types.
Warburg Pincus led a private placement in Allos in 2005 and subsequently participated in a follow-on public offering in 2008. In 2006, Warburg Pincus and the board recruited a new CEO in Paul Berns, former CEO of Bone Care International which he sold to Genzyme for $600 million. Under Paul’s leadership, Allos has successfully developed and launched Folotyn.
